Biotech | April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Supply increase to help meet growing global demand
Highly prestigious award endowed with €500,000 to uphold the United Nations 2030 Agenda
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
The plant is scheduled to come on stream in September 2024
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Subscribe To Our Newsletter & Stay Updated
